Efficacy and safety of a China-developed live attenuated herpes zoster vaccine in Chinese healthy adults aged 40 years and older: a multicentre, randomized, double-blind, placebo-controlled, phase 3 clinical trial.
Shenyu Wang, Pengfei Jin, Yaru Quan, Huakun Lv, Hongxing Pan, Xiaosong Hu, Qi Liang, Yingping Chen, Mingwei Wei, Qiang Lu, Yidi Wang, Zhenzhen Liang, Jian Fu, Na Xu, Zhiping Chen
Clin Microbiol Infect 32(1) 128-136
摘要
摘要
OBJECTIVES: To evaluate the efficacy and safety of a live-attenuated gelatin-free herpes zoster (HZ) vaccine in adults ≥40 years. METHODS: In a multicentre, randomized, double-blind, placebo-controlled phase 3 trial (2020-2021, Zhejiang and Jiangsu provinces), HZ-naïve adults stratified by age (40-49, 50-59, 60-69, and ≥70 years) were randomized 1:1 to receive a single dose of the HZ vaccine (≥4.3 lg PFU) or placebo and followed for 13 months. The primary endpoint was the incidence of HZ; safety outcomes included adverse events (AEs) and serious AEs. RESULTS: The trial included 25 000 participants. HZ incidence was 5.3 versus 12.6/1000 person-years in the vaccine and placebo groups, respectively, resulting in a vaccine efficacy of 57.6% (95% CI: 43.1-68.7%) overall. Per age stratum, vaccine efficacy was 37.4% (95%CI: -117.0% to 83.9%), 62.7% (39.6-77.7%), 64.4% (42.5-78.7%), and 18.63% (-80.4% to 64.0%) in the 40-49, 50-59, 60-69, and ≥70 age groups, respectively. Few postherpetic neuralgia cases occurred (n = 13), limiting vaccine efficacy assessment. Solicited AEs were mild/moderate (13.8% [1719/12 491] vaccine vs. 5.1% [634/12 499] placebo), with no vaccine-related serious AEs. Grade 3 reactions, such as fever, were rare (0.06%, [7/12 491]), and AE rates declined with age (22.0% [219/995] in 40-49 vs. 9.1% [136/1499] in ≥70). DISCUSSION: China's gelatin-free HZ vaccine is safe and moderately effective, particularly in adults aged 50-69 years, with an age-dependent safety profile.
KM 提取结果
0 个 Figure · 0 个 KM 面板